Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Preda

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
United European Gastroenterology Journal|June 19, 2019
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapyCarmen M Preda, Cristian Baicus, Irina Sandra, et al.
Journal of Viral Hepatitis|February 4, 2018
Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirinC M Preda, C P Popescu, C Baicus, et al.
The Lancet. Gastroenterology & Hepatology|January 27, 2018
Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysisMarcus M Mücke, Lisa I Backus, Victoria T Mücke, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 19, 2017
New Epidemiologic Data Regarding Hepatitis C Virus Infection in RomaniaMircea Manuc, Carmen M Preda, Corneliu P Popescu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 18, 2017
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosisCarmen M Preda, Corneliu P Popescu, Cristian Baicus, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
United European Gastroenterology Journal|June 19, 2019
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapyCarmen M Preda, Cristian Baicus, Irina Sandra, et al.
Journal of Viral Hepatitis|February 4, 2018
Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirinC M Preda, C P Popescu, C Baicus, et al.
The Lancet. Gastroenterology & Hepatology|January 27, 2018
Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysisMarcus M Mücke, Lisa I Backus, Victoria T Mücke, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 19, 2017
New Epidemiologic Data Regarding Hepatitis C Virus Infection in RomaniaMircea Manuc, Carmen M Preda, Corneliu P Popescu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 18, 2017
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosisCarmen M Preda, Corneliu P Popescu, Cristian Baicus, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
Pageof 4